Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

432
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

406
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
406
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

601
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
601

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue factor-related biomarkers during combined androgen blockade in patients with prostate cancer: A brief report.

Journal of thrombosis and thrombolysis·2026
Same author

Irregular meal timing and cardiometabolic risk clustering in MASLD: A case-control study.

Clinics and research in hepatology and gastroenterology·2026
Same author

Population-Based Genetic Assessment of Thrombophilia Polymorphisms: Allelic Frequencies and Population Linkage Dynamics.

Medicina (Kaunas, Lithuania)·2025
Same author

Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study.

Journal of global health·2025
Same author

Platelet phagocytosis in acute Dengue infection.

British journal of haematology·2025
Same author

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort.

Blood advances·2025

Related Experiment Video

Updated: Mar 9, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K

Thrombophilia Screening: Universal, Selected, or Neither?

Giuseppe Colucci1,2, Dimitrios A Tsakiris2

  • 11 Service of Hematology, Clinica Luganese Moncucco, Lugano and synlab Suisse, Lucerne, Switzerland.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|January 5, 2017
PubMed
Summary
This summary is machine-generated.

Thrombophilia testing is debated, but may help select young patients, particularly women, to reduce venous thromboembolism (VTE) risk. Comprehensive assessment aids in managing VTE risk for these individuals.

Keywords:
genetic thrombophiliathrombophilia screeningvenous thromboembolism

More Related Videos

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

16.7K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 9, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

16.7K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Area of Science:

  • Medical Science
  • Hematology
  • Genetics

Background:

  • The clinical utility of thrombophilia testing for reducing recurrent venous thromboembolism (VTE) risk remains debated.
  • While not consistently reducing recurrent VTE, thrombophilia testing identifies higher VTE risk in first-time thrombosis patients.

Purpose of the Study:

  • To evaluate the role of thrombophilia testing in managing VTE risk.
  • To identify specific patient groups who may benefit from thrombophilia screening.

Main Methods:

  • Review of studies on thrombophilia testing and VTE risk.
  • Analysis of patient history, clinical examination, and laboratory results, including hereditary thrombophilia markers.
  • Assessment of cumulative VTE risk in selected patient cohorts.

Main Results:

  • Thrombophilia testing has not demonstrated a clear benefit in reducing recurrent VTE in all patients.
  • Screening is indicated for selected individuals, especially young patients and women of childbearing age.
  • Knowledge of genetic thrombophilic defects can inform risk reduction strategies in specific cases.

Conclusions:

  • Comprehensive workup, including thrombophilia testing, is valuable for assessing and managing VTE risk in selected patients.
  • Identifying genetic thrombophilic defects can guide the avoidance of modifiable risk factors and prophylactic measures.
  • Personalized risk assessment incorporating thrombophilia status is crucial for selected patient management.